Senores Pharmaceuticals Q1 FY27 earnings call

Senores Pharmaceuticals Limited delivered a healthy performance in Q1 FY27, with consolidated revenue growing 36% Y-o-Y to INR180 crores and PAT increasing 56% Y-o-Y to INR31 crores. This growth was primarily driven by a robust 42% Y-o-Y revenue increase in the regulated market business. The company's confidence in sustained growth is underpinned by a robust product pipeline, expanded manufacturing footprint, and enhanced R&D capabilities, enabling a healthy performance despite an uncertain operating environment.

The company has significantly expanded its ANDA portfolio, nearly doubling from 30 in June 2025 to 58 approved ANDAs by June 2026. Of these, 23 have been commercialized, with another 35 planned for launch over the next 18 to 20 months. Senores employs a multi-pronged US-driven commercial strategy, including its own labels (Zoraya, Amerisyn), B2B out-licensing, and CDMO/CMO services, ensuring all approved ANDAs have a defined commercial path and are commercially mapped from day one.

Senores has strategically reallocated approximately INR100-120 crores of IPO proceeds, originally earmarked for sterile injectables, towards expanding oral solid capacities in both the US and India. This decision was made to capitalize on the rapid growth of the oral solid portfolio and to generate quicker revenue within 2-5 years. The sterile injectable project will now proceed with a smaller pilot project, pushed to the later half of the current fiscal year, pending shareholder approval for the change in object.

The emerging markets business grew 30% in Q1 FY27 and achieved mid-teens EBITDA margins, becoming cash flow positive with INR18 crores of operating cash generated this quarter. The company is pursuing European PIC/S approval for its Chhatral manufacturing facility by Q2/Q3, which will enhance regulatory credentials and open access to new mid-tier markets like Vietnam and South Africa. This expansion is supported by over 500 registered products and an additional 900+ in the pipeline for emerging markets.

For FY27, Senores Pharmaceuticals expects revenue growth of 30% to 40% and PAT growth of 50% to 60%. The company projects long-term revenue to reach INR2,500 crores to INR3,000 crores within the next three to four years, driven by its diversified product pipeline and market presence. Consolidated EBITDA margins are targeted to be sustained at a minimum of 30%, reflecting a focus on profitability over sales growth in certain segments like India branded generics, which saw INR8 crores in revenue this quarter.